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 The commercialization of research results, understood as their use and dissemination to other entities in a manner that 
allows for financial gain. In this regard, the general rules that apply to the commercial exploitation of economic and trans-
ferable intellectual property rights protecting the results of scientific activities are supplemented with specific statutory 
regulations. They define the procedure for the commercialization of the results of scientific activities carried out in univer-
sities and research institutes, the rights and obligations of researchers in the field of commercialization and the rules for 
distribution of profits from commercialization between the entity and the single author or members of the research teams. 
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Introduction
Scientific research is an indispensable element of modern me-
dicine which seeks increasingly effective ways of solving aging 
societies’ health problems, treating civilization diseases and 
combating threats to public health. A lot of groundbreaking 
applied scientific research is carried out at medical universities 
and research institutes. Their results are the basis for developing 
new treatments, products, devices and medical technologies 
[1]. Apart from scientific publications, the number of patent ap-
plications and implementations based on the research results 
constitutes the criterion of parametric evaluation of scientific 
units and periodic evaluation of researchers. 
Despite some freedom in the management of research 
results, and the acquisition of rights to them, the procedure 
and the distribution of profits from commercialization are 
subject to specific statutory regulations and/or rules applicable 
to funds or grants from which research activities are financed. 
The the knowlege  of these  regulations is essential for the 
effective and profitable management of intellectual property 
related to research results in scientific units, research teams and 
joint projects carried out by clinical departments and entities 
marketing medical products ready for market sales.
Model for commercialization of scientific 
research and development results 
The protection of research results in scientific units researching 
the field of medical sciences is subject to the general provi-
sions of the Act of 4 February 1993 on Copyright and Related 
Rights [2] and the Act of 20 June 2000 Industrial Property Law 
[3]. They concern, in particular, the acquisition by these units 
as an employer of author’s economic rights and industrial 
property rights to intellectual creations. As regards employee’s 
inventions, the law provides  the possibility of participation of 
the author-employee in the benefits obtained from the use 
of the invention (sale or licensing of rights to the invention).
The regulations also include rules of transfer and licensing of 
rights to such results, which, after valuation, may also constitute 
a contribution in kind to a capital company.
Specific rules concerning the management and commer-
cialization of scientific activity results at universities are provi-
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ded by the Act of 20 July 2018. The Law on Higher Education 
and Science [4] and the Act on Research Institutes of 30 April 
2010 on Research Institutes [5], apply to research institutes 
supervised by the Ministry of Health. The regulations as men-
tioned above refer to the “results of scientific research and de-
velopment works and the know-how related to these results”, 
or, a collective term “results of scientific activity”, covering all 
types of such results. These terms also apply to inventions and 
copyright works resulting from development work. Results of 
scientific activity in this sense do not involve scientific work 
(scientific publications, lectures, conference speeches), as well 
as the following not protected by intellectual property rights: 
scientific findings, clinical data, discoveries, results of clinical 
trials “as such”. These creative results are generally outside the 
scope of commercialization processes.
The process of transferring the results of scientific activity 
to practice comprises: 
• direct commercialization, i.e. the sale of results, making 
these results or know-how available for use, in particular 
on the basis of a license, lease and rental agreement; and 
• indirect commercialization, including the acquisition or 
purchase of shares or stocks in companies in order to 
implement the results of scientific activity in exchange for 
the rights to such results and to generate income from this. 
Public universities can carry out indirect commercialization 
through a dedicated university special purpose company (e.g. 
SYNERGIA-WUM Sp. z o. o; the Centre for Innovative Technolo-
gies of the Pomeranian Medical University). With the consent 
of the Minister of Health, medical research institutes can also 
establish capital companies and take up or acquire shares 
and stocks for the purposes of commercialization, conducting 
activities in the field of technology transfer and dissemination 
of science, as well as obtaining funds for statutory activities. 
The units responsible for supporting the commercialization 
processes in research units are technology transfer centers. 
Internal regulations for the management of copyright, indu-
strial property rights and principles of commercialization are an 
essential tool for supporting commercialization processes. They 
regulate the principles, procedure for the commercialization of 
research results created in the research unit and in cooperation 
with external entities in the framework of joint research projects or 
commissioned work. Adoption of such regulations is the respon-
sibility of all research units. In the case of public medical higher 
education institutions and research institutes, they should define: 
• the rights and obligations of the units, employees and 
doctoral students as regard the use of copyright, related 
rights and industrial property rights; 
• the principles of remuneration of authors; 
• the principles of distribution of funds obtained from com-
mercialization; 
• the principles and procedures of commercialization of 
research and development results and the know-how 
related to these results; 
• the principles of using the unit’s property used for the 
commercialization of research results. 
The rules of procedure should be effectively notified to 
employees and form part of their employment contracts.
Rights and obligations of the research unit and 
employees 
The statutory model for the commercialization of research and 
development work in public universities covers the results of 
employees’ scientific activity obtained in the performance of 
their duties, to which the research unit, as the employer, is 
entitled to intellectual property rights. Firstly, its essence is the 
obligation of the entity to decide on the commercialization of 
such results within a specified time.  Secondly, the obligation to 
contractually transfer the rights to such results to the employee 
for a statutorily specified amount if the entity is not interested 
in commercialization, but the employee declares a desire to 
acquire them. Remuneration for the transfer of rights cannot be 
higher than 5% of the average salary in the national economy 
(about 200 PLN). This is a desirable solution for the creator-
-employee, who, for a small amount, can obtain the rights 
to research results and decide on their further commercial 
exploitation, e.g. as part of their business activities. 
At the same time, public universities’ employees have ob-
ligations related to the statutory procedure for the acquisition 
and commercialization of rights to research and development 
results. These include: 
• reporting the results of scientific research and develop-
ment works and the know-how related to these results in 
the procedure specified in internal regulations, 
• transferring all available information and technical expe-
rience needed for commercialization, 
• maintaining the confidentiality of these results.
Sharing commercialization revenue
An essential aspect of the statutory procedure for the com-
mercialization of research and development results is creating 
a financial incentive to develop solutions that can be imple-
mented in practice. In the case of obtaining economic benefits 
from the commercialization of research results at a public uni-
versity (e.g. the sale or licensing of an invention resulting from 
scientific research), the creator-employee is guaranteed by law 
the right to participate in benefits obtained on this account. In 
this case, the employee is entitled to no less than 50% of the 
value of the commercialization funds. It can be reduced by no 
more than 25% of the costs directly related to it (Article 155 of 
the Act on Higher Education and Science). If a research team 
obtained the commercialized results, the indicated minimum 
share of 50% refers to the total remuneration and the alloca-
tion of these funds. In a situation where commercialization is 
carried out by an employee to whom the rights to research 
results have been transferred on the basis of an agreement, 
the employee is required to pay the university 25% of the value 
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of such benefits, reduced by no more than 25% of the costs 
incurred by the employee in direct relation to that activity. 
“Costs directly related to commercialization”, include external 
costs, particularly the costs of legal protection, expert opinions, 
assessment of the value of the object of commercialization 
and official fees incurred to obtain protection (particularly 
patent protection of the invention as an ordinary object of 
commercialization). The right of an employee and the higher 
education institution to remuneration for the benefits from 
commercialization shall last five years from the date of the first 
benefit derived from commercialization. During this period, the 
right to claim remuneration shall be vested in the creator of the 
results regardless of whether or not he/she continues to have 
the status of an employee of the entity.  Therefore the right 
can also be executed after the termination of employment.   
The commercialization of research results 
financed from external sources 
The described statutory rules for commercialization of research 
and development results laid down in the Act on Higher Edu-
cation and Science do not apply to cases where the scientific 
activity which led to the creation of the results was conducted 
on the basis of an agreement with a party financing or co-
-financing this activity and this agreement includes an obli-
gation to transfer the rights to the results of scientific activity 
to this party or to another entity. This also applies to research 
conducted with the use of funds, the rules of granting or use 
of which determine, in an autonomous way, the manner of 
disposing the results of scientific activities and the know-how 
related to these results (e.g. research funds from the National 
Centre for Research and Development (NCBiR), the National 
Science Centre (NCN), European Research Council (ERC) grants, 
EU research grants [6].
Conclusions 
The search for new ways to effectively support health care 
and the treatment of civilization diseases, new possibilities 
of financing research in medicine, increasing cooperation 
between clinical units and entities marketing final medical pro-
ducts is conducive to the intensification of commercialization 
processes of research results. More and more often, they are 
successfully commercialized through companies dedicated to 
this purpose (e.g. PolTREG of the Medical University of Gdansk 
commercializing innovative therapy for diabetes, by using 
T-regulatory lymphocytes taken from the patient’s blood). 
There are also examples of successful licensing on commercial 
terms (e.g. a license to iQure Pharma for a patent protecting 
the Jagiellonian University invention “Modified amino acid 
derivatives for treatment of neurological diseases and selected 
psychiatric disorders“ [7]).
The interest of scientific employees in the implementation 
of their research results is also increasingly influenced by the 
scoring of such achievements in the periodic evaluation of 
scientific employees’ activity and the scientific output assessed 
in the procedures for obtaining scientific degrees and titles.  
Due to the statutory regulation of the commercialization 
of research and development results, public universities, rese-
arch institutes and their researchers are bound by the rights 
and obligations arising from the applicable legislation. They 
can be specified or supplemented in internal regulations on 
the management of copyright and industrial property rights 
and commercialization. Compliance with these regulations 
is subject to control by the authorities supervising these in-
stitutions [8]. 
An important incentive to conduct research that has 
scientific value and can be applied in practice is the right to 
participation in the benefits of commercialization of such 
results. There is also the possibility to purchase rights by 
the employee from the university for a fixed lump sum in 
order to further commercialization. It can be successfully 
conducted through a dedicated company developing and 
offering medical products or services based on such results 
on commercial terms. 
In the case of research and development results obtained 
under grants, multicenter or international projects or coope-
ration with external entities, the rules for the acquisition and 
commercialization of rights to such results may be the subject 
of autonomous regulations, which will be decisive in terms of 
the management of the results of such projects.
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